CROMSOURCE Adds Early Phase Research Unit to its Portfolio
CROMSOURCE srl, an international full service contract research organization announced the completion of a private-public deal with Centro Ricerche Cliniche di Verona (CRC), a modern early phase clinical research unit, founded in 2005. The CRC is located in Verona and is now under state and CROMSOURCE ownership.
The early phase clinical research facilities of the CRC occupy about 800 square metres of the 8th floor of the G.B. Rossi Hospital in Verona. The CRC provides full overnight accommodation and is equipped to state-of-the-art levels. Staff at the CRC has extensive international Pharma experience and the CRC is fully integrated within the local medical and scientific community. This provides access to highly motivated, well-defined patient populations and disease groups for Proof-of-Concept studies.
'We are delighted to welcome CRC and its expert team', stated Dr Oriana Zerbini, Chief Executive Officer of CROMSOURCE. 'For some time we have wanted to add early phase clinical trial capabilities to our comprehensive portfolio of services, and we have now found the perfect way to do so. With this collaboration CROMSOURCE truly becomes a full service CRO, able to provide our customers our support from the earliest part of their clinical development programs.'
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
